I Koza

415 total citations
38 papers, 338 citations indexed

About

I Koza is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, I Koza has authored 38 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in I Koza's work include Cancer Treatment and Pharmacology (11 papers), Testicular diseases and treatments (7 papers) and Neutropenia and Cancer Infections (6 papers). I Koza is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Testicular diseases and treatments (7 papers) and Neutropenia and Cancer Infections (6 papers). I Koza collaborates with scholars based in Slovakia, India and Czechia. I Koza's co-authors include Jozef Mardiak, Michal Mego, Mária Rečková, Zuzana Syčová-Milá, Jana Obertová, J. Trupl, Ava Kwong, Katarína Petráková, Christoph Thomssen and H. Cortés-Funes and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Supportive Care in Cancer.

In The Last Decade

I Koza

36 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I Koza Slovakia 9 190 100 70 53 40 38 338
Marco Ligi Italy 12 167 0.9× 69 0.7× 60 0.9× 82 1.5× 33 0.8× 26 367
David Farrugia United Kingdom 10 236 1.2× 110 1.1× 52 0.7× 150 2.8× 34 0.8× 29 429
Tapan Bhavsar United States 11 86 0.5× 82 0.8× 87 1.2× 77 1.5× 22 0.6× 26 346
Leno Thomas United States 7 138 0.7× 86 0.9× 28 0.4× 112 2.1× 27 0.7× 8 324
M. Ruud Halie Netherlands 13 85 0.4× 115 1.1× 52 0.7× 20 0.4× 14 0.3× 18 448
Keisuke Okuno Japan 11 133 0.7× 42 0.4× 93 1.3× 112 2.1× 25 0.6× 42 310
Tai‐Kwong Chan China 10 87 0.5× 119 1.2× 219 3.1× 54 1.0× 43 1.1× 14 467
Minoru Nakane Japan 7 339 1.8× 144 1.4× 64 0.9× 43 0.8× 18 0.5× 12 431
Semin Ayhan Türkiye 11 78 0.4× 49 0.5× 152 2.2× 54 1.0× 18 0.5× 41 347
Rimma Goldberg Australia 12 88 0.5× 89 0.9× 139 2.0× 24 0.5× 10 0.3× 35 488

Countries citing papers authored by I Koza

Since Specialization
Citations

This map shows the geographic impact of I Koza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I Koza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I Koza more than expected).

Fields of papers citing papers by I Koza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I Koza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I Koza. The network helps show where I Koza may publish in the future.

Co-authorship network of co-authors of I Koza

This figure shows the co-authorship network connecting the top 25 collaborators of I Koza. A scholar is included among the top collaborators of I Koza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I Koza. I Koza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Smith, Ian E., Jean‐Yves Pierga, Laura Biganzoli, et al.. (2010). First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology. 22(3). 595–602. 81 indexed citations
3.
Šufliarský, Jozef, Jozef Chovanec, Daniela Světlovská, et al.. (2009). Gemcitabine and carboplatin treatment in Patients with relapsing ovarian cancer. Neoplasma. 56(4). 291–297. 4 indexed citations
4.
Kornek, Gabriela, Werner Scheithauer, Rodica Maricela Anghel, et al.. (2008). Consensus on the medical treatment of colon cancer. memo - Magazine of European Medical Oncology. 1(2). 79–90. 6 indexed citations
5.
Ciuleanu, Tudor–Eliade, G. Kurteva, Janja Ocvirk, et al.. (2008). A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 26(15_suppl). 4032–4032. 9 indexed citations
6.
Mardiak, Jozef, Zuzana Syčová-Milá, Jana Obertová, et al.. (2007). Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.. PubMed. 54(3). 240–5. 11 indexed citations
7.
Mego, Michal, Eva Ballová Mikušková, Ľuboš Drgoňa, et al.. (2005). Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Supportive Care in Cancer. 14(3). 285–290. 30 indexed citations
8.
Mardiak, J., Zuzana Syčová-Milá, Jana Obertová, et al.. (2004). Paclitaxel, ifosfamide, and cisplatin (TIP) salvage therapy for patients (pts) with relapsed testicular germ cell tumors (GCT). Journal of Clinical Oncology. 22(14_suppl). 4632–4632. 4 indexed citations
9.
Mardiak, J., et al.. (2000). Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.. PubMed. 47(4). 239–43. 2 indexed citations
10.
Krčméry, V., I Koza, Jozef Mardiak, et al.. (1992). Netilmicin plus Ceftriaxone versus Amikacin plus Ceftriaxone in the Treatment of Infections in Granulocytopenic Patients. Chemotherapy. 38(1). 74–76. 3 indexed citations
11.
12.
Koza, I, J. Mardiak, L Švancárová, et al.. (1992). Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas--long-term observation.. PubMed. 39(1). 43–7. 2 indexed citations
13.
Krčméry, V., et al.. (1991). Nephrotoxicity of Aminoglycosides, Polypeptides and Cephalosporins in Cancer Patients. Chemotherapy. 37(4). 287–291. 4 indexed citations
14.
Krčméry, V., et al.. (1991). Fluconazole in the Treatment of Mycotic Oropharyngeal Stomatitis and Esophagitis in Neutropenic Cancer Patients. Chemotherapy. 37(5). 343–345. 2 indexed citations
15.
Eckhardt, S., Krsto Kolarić, J Jassem, et al.. (1990). Phase II study of 4'-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG).. PubMed. 7(1). 19–23. 7 indexed citations
16.
Juhos, É, S Jelić, I Koza, et al.. (1988). Activity of Epirubicin and Dibromodulcitol in Advanced Breast Cancer. Oncology. 45(6). 409–412. 2 indexed citations
17.
Koza, I, et al.. (1988). Therapy of P388 leukemia with benzaldehyde.. PubMed. 35(6). 725–8. 2 indexed citations
18.
Stjernswärd, Jan, et al.. (1986). National cancer control programs and setting priorities.. PubMed. 9(1-2). 113–24. 4 indexed citations
19.
Koza, I, Holland Jf, & E. Cohen. (1971). Histocompatible leukocyte transfusion during granulocytopenia.. PubMed. 18(2). 185–91. 13 indexed citations
20.
Koza, I, et al.. (1969). Blastic crisis of chronic myelogenous leukaemia.. PubMed. 16(4). 417–26. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Ligi Breakdown of academic impact, for papers by David Farrugia Breakdown of academic impact, for papers by Tapan Bhavsar Breakdown of academic impact, for papers by Leno Thomas Breakdown of academic impact, for papers by M. Ruud Halie Breakdown of academic impact, for papers by Keisuke Okuno Breakdown of academic impact, for papers by Tai‐Kwong Chan Breakdown of academic impact, for papers by Minoru Nakane Breakdown of academic impact, for papers by Semin Ayhan Breakdown of academic impact, for papers by Rimma Goldberg
Rankless by CCL
2026